A study was conducted to investigate the relationship between energy systems and running performance, especially during the last spurt in an 800-m race. The subjects were separated into good 800-m runners (group A n=5: best record, 1′54″3±1.4) and a second group of slower 800-m runners (group B n=4: best record, 2′02″1±1.3) . Each group executed two types of running test (600m test and 800m test) . To simulate an 800-m race, the running speed up to 600m was set by means of a lamp pace maker system. The last spurt was running 200m at maximal voluntary running speed. Plasma lactate, plasma ammonia, serum glucose and blood pH were assayed at rest, after warming up, and 6 and 10min after the running test.
The following results were obtained:
1) The last spurt time of group A was significantly faster than that of group B (p<0.01) . 2) In group A, plasma lactate and plasma ammonia concentrations increased significantly during the last spurt (p<0.05) . In group B, however, plasma lactate and plasma ammonia concentrations before the last spurt (600m test values) were very close to the values after the last spurt (800m test values), 3) Last spurt times were significantly related to changes in plasma lactate concentration (r=-0.870, p<0.01) and O² debt (r=-0.799, p<0.01) during the last spurt.
These results suggest that running performance during the last spurt in an 800-m race depends on anaerobic energy ability, as reflected by plasma lactate, plasma ammonia and O² debt before the last spurt.

BACKGROUND/AIMS: This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using viral response within 2 weeks. METHODS: Low-dose PEG-IFN-α-2b plus ribavirin was administered to 50 elderly and/or cirrhotic patients with genotype 2 HCV for 24 weeks. The dynamics of HCV RNA and HCV core antigen levels within 2 weeks were measured. RESULTS: The patients' median age was 66 years. There were 21 male and 29 female patients. The median baseline HCV RNA level was 5.7 log IU/mL. Rapid viral response was achieved in 17 patients (34%), SVR in 28 (56%), and two (4%) discontinued treatment. Univariate analysis of factors contributing to SVR showed significant differences for sex, baseline virus level, and response within 4 weeks. When 40 fmol/L was set as the cutoff value for the core antigen level at 1 week, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for predicting SVR were 93%, 75%, 84%, 88%, and 85%, respectively. CONCLUSIONS: Low-dose PEG-IFN plus ribavirin was a safe and cost-effective treatment for elderly and/or cirrhotic patients with genotype 2 HCV, and the viral response within 2 weeks was a useful predictor of SVR.
Aged* ; Female ; Genotype* ; Hepacivirus* ; Hepatitis C* ; Hepatitis* ; Humans ; Interferons* ; Liver Cirrhosis ; Male ; Ribavirin* ; RNA ; Sensitivity and Specificity